ESTEVE's Promising Acquisition of Caprelsa® to Treat Medullary Thyroid Cancer ESTEVE has secured the rights to Caprelsa® (vandetanib) in over 50 countries, a significant drug for treating medullary thyroid cancer in both adults and children, signaling notable international growth for the company.

ESTEVE's Promising Acquisition of Caprelsa® to Treat Medullary Thyroid Cancer #Spain #Barcelona #ESTEVE #Caprelsa® #Medullary_Cancer